Bod

Rapid Whole Blood Testing for Infectious Mononucleosis Antibodies

The Epstein Barr virus (EBV), which causes infectious mononucleosis (IM), is one of the most common human viruses. EBV occurs worldwide, and most people become infected with EBV sometime during their lives. In the United States, as many as 95 percent of adults between 35 and 40 years of age have been infected. In most developed countries, including the U.S., infection with EBV most often occu...

Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease

- Publication of New Cardiovascular Target from Lexicon's GeneticResearch - THE WOODLANDS, Texas, July 02, 2007 /PRNewswire-FirstCall/ --Lexicon Pharmaceuticals, Inc. today reported results frompreclinical research demonstrating that antibodies directed to apotential new target, angiopoietin-like protein 4 (ANGPTL4),rapidly lower triglycerides and cholesterol. Research suggests thata mon...

Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)

GHENT, Belgium, 2 July, 2007 -- Ablynx today announced positiveinterim results from the ongoing Phase I study of its leaddevelopment programme, ALX-0081, an anti-thrombotic treatment.ALX-0081 is a novel ´first-in-class´ therapeuticNanobody® targeting von Willebrand Factor (vWF), which canreduce the risk of thrombosis in patients with acute coronarysyndrome. The Pha...

Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood

Preclinical Studies Show 227Th-rituximab More Effective atKilling CD20-Positive Lymphoma Cells Than 90Y-tiuxetan-ibritumomab(Zevalin) OSLO, Norway, 14 June 2007 - Algeta ASA (OSE: ALGETA), theNorwegian cancer therapeutics company, announces that a researchpaper showing the potential of its TH-1 technology for targetedcancer therapy has been published by the leading medical journal,...

Mymetics' HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model

NYON, Switzerland, June 07, 2007 /PRNewswire-FirstCall/ --Mymetics Corporation announced today analysis of resultsdemonstrating that the Company's HIV vaccine elicited neutralizingIgA mucosal antibodies in a non-human primate model. Mucosal IgAantibodies are considered as a possible first line of defenseagainst infection by HIV. The data were presented by SylvainFleury, Ph.D., Mymetics'...

Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 5, 2007 - ElixirPharmaceuticals, Inc., announced today new preclinical dataconfirming ghrelin antagonism as a potential method for regulatingmetabolism, decreasing body weight and managing blood glucose. Thedata were presented in poster sessions during ENDO 07, TheEndocrine Society's 89th Annual Meeting, being held in Toronto,Canada. Elixir is focused...

Phase I Results for ImClone Pipeline Anti-IGF-1R Monoclonal Antibody IMC-A12 Presented at ASCO

NEW YORK--(BUSINESS WIRE)--Jun 5, 2007 - First-in-human results forIMC-A12, a monoclonal antibody developed by ImClone SystemsIncorporated (NASDAQ: IMCL) and targeted to IGF-1R (insulin-likegrowth factor type 1 receptor), were presented at the annualmeeting of the American Society of Clinical Oncology in Chicago.The IGF-IR is expressed on the cell surface of must human cancersand transmits...

Vical's Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues

MALAGA, Spain, May 23, 2007 /PRNewswire-FirstCall/ -- VicalIncorporated today announced that in a recently completed animalstudy, a DNA vaccine formulated with the company's patentedVaxfectin(TM) adjuvant and delivered by needle-free injectionyielded significantly higher antibody responses than anunformulated DNA vaccine delivered by needle and syringe. In aseparate animal study, electro...

Human Genome Sciences Reports Growing Evidence That Its TRAIL Receptor Antibodies Have Significant Potential in the Treatment of a Broad Range of Cancers

- Journal of Clinical Oncology publishes first clinical study ofHGS-ETR1 - ROCKVILLE, Md., April 27, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today reported that clinical and preclinicalevidence continues to emerge demonstrating that its TRAIL receptorantibodies, HGS-ETR1 (mapatumumab) and HGS-ETR2 (lexatumumab), havesignificant potential for use in the treatment of a bro...

Positive Results Using Affitech-Identified Human Antibody That Blocks VEGF Binding to VEGF Receptor 2 in Preclinical Cancer Model Reported by Peregrine

OSLO, Norway--(BUSINESS WIRE)--Apr 23, 2007 - Affitech AS, thehuman antibody therapeutics company announced today that PeregrinePharmaceuticals, Inc. reported positive in vivo test results of R3,a fully human monoclonal antibody developed by Affitech, in apancreatic cancer model at the recently concluded Centennial AnnualMeeting of the American Association for Cancer Research (AACR). R3has...

Seattle Genetics Highlights Data on its Proprietary Antibody-Drug Conjugate Technology at AACR

BOTHELL, Wash. & LOS ANGELES--(BUSINESS WIRE)--Apr 17, 2007 -Seattle Genetics, Inc. (Nasdaq: SGEN) today announced data fromfifteen presentations by the company and its collaborators at the2007 Annual Meeting of the American Association for Cancer Research(AACR) demonstrating preclinical advances with its proprietaryantibody-drug conjugate (ADC) technology and cancer productpipeline.<p...

Viventia biotech reports synergystic effect of its Proxinium antibody in combinaton with chemotherapy and radiation

- Results Reported at the American Association for Cancer Research(AACR) Annual Meeting - TORONTO, April 18, 2007 /PRNewswire/ - Viventia Biotech Inc., aprivately held biopharmaceutical company advancing a portfolio ofnovel antibody products focused on cancer, today announced resultsof in vitro cytotoxicity and in vivo pharmacokinetic studiesconducted to evaluate the potential for combini...

Medarex Presents Preclinical Data Demonstrating Potent Anti-Tumor Activity of Anti-CD19 and Anti-CD70 Antibody-Drug Conjugates in Cancer Animal Models

- Data presentations at American Association for Cancer Researchannual meeting - PRINCETON, N.J., April 17, 2007 /PRNewswire-FirstCall/ --Medarex, Inc. today presented preclinical data demonstrating potentanti- tumor activity from two separate studies exploring theefficacy and safety in animal models of anti-CD19 and anti-CD70antibody-drug conjugates. CD19 and CD70 are both attractive tar...

Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response

SOUTH SAN FRANCISCO, Calif., April 17, 2007/PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported immuneresponse data from two previously conducted Phase 2 clinical trialsof GVAX immunotherapy for prostate cancer. Evaluation of antibodyresponses in patients with advanced prostate cancer from thesestudies shows that the GVAX cell-based immunotherapy inducesantibody responses to a bro...

Data Presented at AACR Meeting Shows Peregrine's Selective Anti-VEGF Antibodies are as Effective as Avastin(R) in Preclinical Cancer Models

- Peregrine's Selective Anti-VEGF Antibodies Inhibited Tumor Growth By 90% In a Preclinical Cancer Model - - Peregrine's Antibodies that Selectively Inhibit VEGF Receptor2 Could - These Results Along with Data Presented on a Fully HumanAntibody Support Advancing Peregrine's...

Large Study Shows that Presence of Neutralizing Antibodies Did Not Predict Clinical Response to Betaseron Treatment

WAYNE, N.J., April 02, 2007 /PRNewswire/ -- Berlex, Inc., a U.S.affiliate of Bayer Schering Pharma AG, Germany, announced today theresults of a retrospective study demonstrating that the presence ofneutralizing antibodies (NAbs) that can develop in response toBetaseron(R) (interferon beta-1b) therapy did not predict clinicalresponse in patients with multiple sclerosis (MS).(1) The studyl...

Anthrax Monoclonal Antibody Valortim(tm) Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax Infection

Pilot Study Demonstrates 50% Survival in Valortim-TreatedAnimals PRINCETON, N.J. and ANNAPOLIS, MD., March 29, 2007 - Medarex,Inc. (Nasdaq: MEDX), a leading monoclonal antibody company, andPharmAthene, Inc., a privately held biotechnology company dedicatedto the development of biodefense countermeasures, today announcedthat Valortim, a fully human monoclonal antibody product candid...

Mymetics' HIV Vaccine Achieves Research Breakthrough, Eliciting Protective Antibody Response in Mucosal Tissues of Non-Human Primate Model

Mymetics Also Announces Deal for Vaccine Delivery System NYON, Switzerland, March 29, 2007 /PRNewswire-FirstCall/ --Mymetics Corporation announced today that the Company's HIV vaccineelicited IgA mucosal antibodies in a non-human primate model.Mucosal IgA antibodies are considered a possible first line ofdefense against infection by HIV. The data were presented bySylvain Fleury, Ph.D., My...

Anthrax Monoclonal Antibody Valortim Demonstrates Therapeutic Effect in New Primate Model of Established Anthrax Infection

Pilot Study Demonstrates 50% Survival in Valortim-Treated Animals PRINCETON, N.J. and ANNAPOLIS, Md., March 29, 2007/PRNewswire-FirstCall/ -- Medarex, Inc. , a leading monoclonalantibody company, and PharmAthene, Inc., a privately heldbiotechnology company dedicated to the development of biodefensecountermeasures, today announced that Valortim(TM), a fully humanmonoclon...

Alfacell's Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies

BLOOMFIELD, N.J., March 20, 2007 /PRNewswire-FirstCall/ --Alfacell Corporation's ONCONASE (ranpirnase) has shown potential toact as a potent payload in antibody conjugates for cancer therapy,according to the latest edition of the Handbook of TherapeuticAntibodies. In a chapter of the text that reviews immunotoxins, SusannaRybak, Ph.D. summarizes preclinical research indicating that...

La Jolla Pharmaceutical Provides Update on Interim Antibody Results From Riquent Lupus Phase 3 Trial

SAN DIEGO, March 20, 2007 /PRNewswire-FirstCall/ -- La JollaPharmaceutical Company today announced updated interim antibodyreduction data for the Phase 3 trial of Riquent(R) (abetimussodium), its drug candidate for systemic lupus erythematosus("lupus" or "SLE"). The updated analyses reinforce the previousconclusion that there is a definitive and significant dose responsebetween the 100 m...

La Jolla Pharmaceutical Announces Positive Interim Antibody Results From Riquent Lupus Phase 3 Trial

Data Support Ability of Higher Doses to Further Reduce Antibodiesto Double-Stranded DNA SAN DIEGO, March 08, 2007 /PRNewswire-FirstCall/ -- La JollaPharmaceutical Company today announced positive interim antibodyresults from its ongoing double-blind, placebo-controlledrandomized Phase 3 trial of Riquent(R) (abetimus sodium), its drugcandidate for systemic lupus erythematosus ("lupus" or "...